In-stent restenosis in the renal arteries: The role of brachytherapy

Vascular Disease Management

Volumn 3, Issue 1, 2006, Pages 184-

  Shammas, Nicolas W ^a  

^a MIDWEST CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IRIDIUM 192;

BRACHYTHERAPY; DRUG ELUTING STENT; EVALUATION; FOLLOW UP; GAMMA BRACHYTHERAPY; GAMMA RADIATION; HUMAN; IN-STENT RESTENOSIS; KIDNEY ARTERY STENOSIS; NEPHROSCLEROSIS; NOTE; OUTCOME ASSESSMENT; PREDICTION; RISK FACTOR; SAMPLE SIZE; SMOKING; STENT;

EID: 33747078451     PISSN: 15538036     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (6)

1. Shammas NW, Kapalis MJ, Dippel EJ, et al. Clinical and angiographic predictors of restenosis following renal artery stenting. J Invasive Cardiol 2004;16:10-13.
2. Vignali C, Bargellini I, Lazzereschi M, et al. Predictive factors of in-stent restenosis in renal artery stenting: A retrospective analysis. Cardiovasc Intervent Radiol 2005;28:296-302.
3. Nolan BW, Schermerhorn ML, Powell RJ, et al. Restenosis in gold-coated renal artery stents. J Vasc Surg 2005;42:40-46.
4. Bax L, Mali WP, Van De Ven PJ, et al. Repeated intervention for in-stent restenosis of the renal arteries. J Vasc Interv Radiol 2002;13:1219-1224.
5. Stoeteknuel-Friedli S, Do DD, von Briel C, et al. Endovascular brachytherapy for prevention of recurrent renal in-stent restenosis. J Endovasc Ther 2002;9:350-353.
6. Jahraus CD, St Clair W, Gurley J, Meigooni AS. Endovascular brachytherapy for the treatment of renal artery in-stent restenosis using a beta-emitting source: A report of five patients. South Med J 2003;96:1165-1168.